Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-185 in newly diagnosed transplant-ineligible multiple myeloma
2015-002901-12Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Pembrolizumab + lenalidomide + low-dose dexamethasone with Lenalidomide + low-dose dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-002901-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002901-12.